Allogeneic hematopoietic SCT (HSCT) remains the only curative but highly successful treatment for sickle cell disease. 1 HSCT may be an acceptable treatment for patients with severe systemic lupus erythematosus (SLE). 2 We report our experience of matched sibling HSCT in an 11-year-old girl with sickle cell disease complicated by SLE. The post transplant course was complicated by posterior leukoencephalopathy syndrome with status epilepticus secondary to cyclosporine toxicity, gastroduodenitis probably due to mycophenolate mofetil treatment, and mild acute and chronic graft-versus-host disease (GVHD). To the best of our knowledge, this is the first successful HSCT of concurrent sickle cell disease and SLE.
A Bahraini girl with sickle cell-b thalassemia had mild anemia (baseline Hb 8-9 g/dl) and infrequent crisis until the age of 8 years when she presented with recurrent arthralgia, malar rashes, cutaneous vasculitis, hepatosplenomegaly, mild proteinuria and Coombs-positive hemolysis. The diagnosis of SLE was made with the positive findings of anti-dsDNA antibodies. Since then, her clinical course had been complicated by monthly to bimonthly attacks of overlapping sickle cell crises and flaring up of SLE with fever, rashes, bone pains, arthralgias. She was eventually put on regular red cell transfusion or exchange transfusion, intermittent pulses of i.v. methylprednisolone as well as prolonged oral prednisolone therapy, ibuprofen and inhaled bronchodilation for obstructive airway disease. During the first year of her illness with SLE, she had one episode of generalized convulsion associated with posterior leukoencephalothy on magnetic resonance imaging (MRI) but no vascular changes on the magnetic resonance angiography. The abnormalities disappeared a year later on repeat imaging. Treatment with deferasirox was commenced for transfusion hemosiderosis. In view of the frequent veno-occlusive crises and regular blood transfusions associated with sickle cell disease, she was considered a candidate for allogeneic HSCT.
In August 2009, when she was 11 years old, she received a PBSC transplant from her HLA-matched brother after conditioning with oral BU, i.v. cyclophosphamide, and rabbit anti-thymocyte globulin. The initial GVHD prophylaxis was with cyclosporine and short MTX. A single dose of pegfilgrastim 4 mg (0.14 mg/kg) was given on Day þ 2. Neutrophils recovered to 40.5 Â 10 9 /l by Day þ 14 with 100% donor chimerism and she was free from red cell transfusion by Day þ 23.
The early post transplant period was complicated by febrile neutropenia and severe colitis. Starting from Day þ 28, skin GVHD developed (maximum, grade III) without gut or liver involvement. The skin rashes responded to a 5-day course of iv methylprednisolone 2 mg/kg per day and oral mycophenolate mofetil 500 mg/m 2 twice daily. Thereafter, the GVHD treatment was continued with oral cyclosporine and mycophenolate.
On Day þ 42, she was admitted to the intensive care unit after presenting with prolonged generalized tonic, clonic seizures that failed to respond to iv diazepam. There was a prodrome of severe headache in the morning, but blood pressure measurements were normal after stabilization. Plasma glucose, electrolytes including calcium and magnesium were normal. Cyclosporine level was 322 ng/ml. Seizures were aborted with iv midazolam infusion and levetiracetam. She became fully conscious 12 h after admission, but vision was blurred during the next 48 h. An urgent MRI showed white matter changes in the left temporo-occipital lobe and left occipital lobe consistent with posterior leukoencephalopathy, with no signs of bleeding or infarction. A diagnosis of status epilepticus secondary to posterior leukoencephalopathy syndrome was made. Tacrolimus was substituted for cyclosporine. No recurrence of seizure occurred and anticonvulsants were stopped 4 weeks later.
She was diagnosed endoscopically with gastroduodenitis during the third month post transplant. Gastric biopsy showed signs of chronic inflammation with apoptotic bodies compatible with either GVHD or mycophenolate-induced gastrointestinal injury. 3 Her gastrointestinal symptoms resolved with treatment with esomeprazole and low-dose prednisolone 0.5 mg/kg per day, and cessation of mycophenolate therapy.
Skin GVHD recurred during the third month after transplant and gradually resolved by the end of the first year. Both antinuclear and anti-dsDNA antibodies became undetectable 2 months after the transplant. She is currently well, being free from neurological symptoms and proteinuria, without any immunosuppressant treatment at 31 months post transplant.
Either sickle cell disease or SLE, in the presence of severe complications, is an indication of HSCT.
1,2 Most of the reported experience in SLE involves the use of autologous stem cells, though allogeneic HSCT has been used in more refractory cases. 4 Children with sickle cell disease may be at risk of developing SLE 5 , which, as illustrated in this case, makes life more difficult. Thus, HSCT is an appealing treatment when a child is affected by both conditions simultaneously.
Neurologic complications appear to be more common in children with sickle cell disease undergoing bone marrow transplantation. Walters et al. 6 first noted seven out of 21 recipients developed either seizures and/or intracranial hemorrhage post transplant. In a more recent report, Majumdar et al. 1 reported four out of 10 children with sickle cell disease who experienced similar complications after HSCT. Those who have a history of stroke appear to be at higher risk. The use of cyclosporine for the management of GVHD may be another risk factor for pediatric recipients with hemoglobinopathies. 1, 6, 7 Our case suggests that SLE with prior central nervous involvement can be another risk factor.
In summary, children with sickle cell disease complicated by SLE should be considered for HSCT. They are, however, at high risk of neurological complications. Whether the use of alternative calcineurin inhibitors other than cyclosporine is protective deserves further studies.
